Faron share placement is fully subscribed

Faron Pharmaceuticals Oy has raised £10 million, before expenses, in a private share placement to support the late-stage development and commercialisation of its product for acute respiratory distress syndrome Traumakine. Current and new investors supported the offering.

Full text available to subscribers only. Click here for information on subscribing to MedNous.